Stanford Advisors


All Publications

  • RIPK3: A New Player in Renal Fibrosis. Frontiers in cell and developmental biology Shi, Y., Chen, X., Huang, C., Pollock, C. 2020; 8: 502


    Chronic kidney disease (CKD) is the end result of a plethora of renal insults, including repeated episodes of acute or toxic kidney injury, glomerular, or diabetic kidney disease. It affects a large number of the population worldwide, resulting in significant personal morbidity and mortality and economic cost to the community. Hence it is appropriate to focus on treatment strategies that interrupt the development of kidney fibrosis, the end result of all forms of CKD, in addition to upstream factors that may be specific to certain diseases. However, the current clinical approach to prevent or manage renal fibrosis remains unsatisfactory. The rising importance of receptor-interacting serine/threonine-protein kinase (RIPK) 3 in the inflammatory response and TGF-beta1 signaling is increasingly recognized. We discuss here the biological functions of RIPK3 and its role in the development of renal fibrosis.

    View details for DOI 10.3389/fcell.2020.00502

    View details for PubMedID 32613000

Footer Links:

Stanford Medicine Resources: